Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I admit to being furious. I always hated short sellers, but when the SEC comes to their rescue, that crosses the line. What the market did in response to the Reddit board attack on the Hedge fund shorts (some of which exceeded 100%) is inexcusable. Hedge fund shorters are EVIL; they drive stocks to zero and feast off the carcasses of the dead, and the SEC comes to their rescue when they are squeezed. They don't raise a finger to aid companies or investors when shorts drive companies under, but somehow when the shorts are squeezed that requires action to halt trading and prohibit buying. Plus the boards stop the Reddit posts as "hate speech"
This is an insane world.
Opti
News Release Issued: Jan 28, 2021 (9:30am EST)
To view this release online and get more information about Newsroom | Co-Diagnostics, Inc. visit: https://news.codiagnostics.com/2021-01-28-Co-Diagnostics-Completes-FDA-EUA-Submission-for-Extraction-Free-Saliva-COVID-19-Test
Co-Diagnostics Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test
The Company's Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test is designed to reduce sample processing time and cost by eliminating the extraction process
SALT LAKE CITY, Jan. 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed its submission to the U.S. Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) of its Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test, a COVID-19 polymerase chain reaction (PCR) diagnostic designed to detect the presence of SARS-CoV-2 in human saliva samples without first requiring RNA extraction of the sample.
The Company's new Direct Saliva test is designed to reduce sample processing time and cost by eliminating extraction
PCR tests usually require a costly, time-consuming process intended to extract any genetic material present from the cells contained in the sample. These extracted samples are then analyzed for the presence of the target pathogen using PCR technology. Co-Diagnostics' Logix Smart SARS-CoV-2 DS test was developed following the Company's announcement that its patented CoPrimer™ technology was shown to be able to consistently detect SARS-CoV-2, the virus that causes COVID-19, directly from minimally processed saliva samples. The Company believes that eliminating the extraction process has the potential to increase throughput and lower costs of COVID-19 testing, all without compromising quality or accuracy.
"Our new extraction-free saliva test has been developed as part of our ongoing commitment to providing improved COVID-19 diagnostics for high-throughput laboratory settings, using technology with additional potential point-of-care applications," said Dwight Egan, Co-Diagnostics CEO. "We believe that this technology will help to meet the domestic and global need for high-quality COVID-19 tests that can be processed quickly and affordably, while retaining the advantages of PCR testing over other testing alternatives. It also represents a major step forward in a new generation of PCR tests that can be widely more accessible, and we look forward to offering additional cutting-edge molecular diagnostic tools in the continuing battle against COVID-19 and other diseases."
I have truly despised hedge fund shorters for years. They are evil.
Now we see them beaten at their own game and the SEC comes to their rescue. Incredible.
https://www.foxnews.com/media/payne-gamestop-wall-street-short-sellers
Opti
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Co-Diagnostics (CODX) now clears that threshold, with a jump from 66 to 83 Wednesday.
https://www.investors.com/ibd-data-stories/co-diagnostics-shows-market-leadership-with-jump-to-83-rs-rating/
Opti
So apparently there was a list on Reddit. Unfortunately it got the attention of Hedge Fund shorters and they somehow got the thread shut down. That is why the short squeeze stocks dropped AH. Don't know where this goes tomorrow.
Opti
Biden administration considers mandatory COVID-19 tests for domestic air travel, official says
'We realize that there’s been a dramatic evolution and increase in both testing platforms and testing capacity'
https://www.foxnews.com/politics/biden-administration-considers-mandatory-covid-19-tests-for-domestic-air-travel-official-says
Opti
Several prominent short squeezes across the market. Hopefully CODX is on the list.
Opti
From:https://msmoneymoves.com/daily-trade-insights/
A COVID-19 testing stock we have traded a number of times in 2020, for a refresher and updated findings please see below
CODX is a Utah-based molecular diagnostics company leveraging its proprietary platform ( Logix Smart™) for detecting/analyzing DNA/RNA samples
CODX is also working to refine and produce test kits which can provide an accurate pulse on new variants of COVID-19 which are beginning to emerge
Recently presented at the H.C. Wainwright BioConnect virtual conference
Retraced 65% from its 52-week high of $30.99 set on 8/4/20 with no negative developments and strong commercial performance YTD (~$48M in total sales as of 9/30/20)
As infections continue to grow, demand for CODX products appears to be high with CODX anticipating their highest quarterly sales
CODX is able to deliver competitive PCR-based diagnostic tests at lower price points than its competitors b/c of its proprietary platform which allows the company to avoid paying patent royalties
Received emergency use authorization on 4/3/20 for its COVID-19 tests
CODX was the first U.S-based company to receive a CE mark in the EU for a COVID-19 test
On 9/8/20 CODX entered into an agreement with Arches Research enabling the company to expand the commercial reach of its COVID-19 test kit
Of note, as of 9/30/20, CODX had 90% of its 1M+ warrants exercised leaving ~100K outstanding. CODX’s total cash position was ~$27M
Monitoring to enter on weakness and trade into upcoming earnings and other 2021 catalyst
Support to watch = $11.46
Resistance to watch = $14.95
Risk est = Yellow
PT = $12.50-13+ (0-2 weeks)
Big: I am a little concerned about Dwight's statements about earnings. I would rather he simply talked about contracts. It bothers me they don't seem to have much of a marketing department. If they did, they surely would be expanding production.
I know they value accuracy, but it appears the money is in quick results, so I wish they would expand and produce some form of quick-result test that exceeds the others in accuracy.
I also need to hold until March and June for tax purposes, but if we hit $30 again in February, I will watch the pps very closely. I will not hold like I did last year while the price dropped. I could have paid the difference in taxes 5 times over had I sold at $30 and bought back at $8.
I don't understand the low volume, the constant shorting, and the failure of CODX to gain traction, hit $25 and hold for earnings. How this is so manipulated is a mystery.
I wish we had some posters on this board that know what is going on. There is no discussion of CODX on any of the stock forums, period.
Opti
We need to drum up some action on this board. I am weary of talking to myself.
Opti
We need to drum up some action on this board. I am weary of talking to myself.
Opti
We need to drum up some action on this board. I am weary of talking to myself.
Opti
We need to drum up some action on this board. I am weary of talking to myself.
Opti
'Hard truths and important facts': Biden pushes for coronavirus testing reset with $50 billion plan
Ken Alltucker, USA TODAY 54 mins ago
Trump 'Does Want to Run Again,' Says Former Acting Intelligence Chief Richard…
Tom Brady Is Getting Criticized For His Postgame Move
USA TODAY logo'Hard truths and important facts': Biden pushes for coronavirus testing reset with $50 billion plan
President Joe Biden seeks to reset the nation’s inconsistent coronavirus testing efforts with a $50 billion plan and more federal oversight.
https://www.msn.com/en-us/news/us/hard-truths-and-important-facts-biden-pushes-for-coronavirus-testing-reset-with-50-billion-plan/ar-BB1d2Pmu?ocid=msedgdhp
Biden’s plan calls for a newly created Pandemic Testing Board to coordinate a “clear, unified approach” to testing for COVID-19, a marked difference from the Trump administration’s policy of states establishing their own plans with federal support.
Laboratories have ramped up production to more than 2 million tests each day, but stubborn problems persist. Some labs struggle to complete timely tests – particularly when demand surges – because of shortages of critical supplies.
Public health labs largely are not equipped to detect new coronavirus variants such as ones first identified in the United Kingdom and South Africa. And there's debate among testing experts on whether wider use of cheaper but less sensitive rapid tests will be the smartest path out of the pandemic.
and at federal facilities, except when it is him and he is celebrating his election.
Opti
Pandemic Testing Board Executive Order Signed by the President at 3:10 PM today. If I were President of CODX I would be aggressively pursuing the following:
1. Creation of a marketing division that visited every state and every major industry to sell the CODX testing product.
2. Work contacts in government to establish agreements and funding.
3. Work to establish partners in the production and sale of CODX tests.
4, Work with stock funds to purchase shares.
5. Expand contracts and issue PRs on a continual basis.
6. Double production.
7. Communicate with stock holders.
8. Expand, expand, expand.
9. Communicate, communicate, communicate.
10. Acknowledge and respond to shareholder emails.
Opti
Scale and expand testing. To control the COVID-19 pandemic and safely reopen
schools and businesses, America must have wide-spread testing. A national
testing strategy is a cornerstone to reducing the spread of COVID-19 and
controlling outbreaks, and clear federal guidance and a unified national approach to
implementation are essential. The President will issue Executive Order Establishing
the National Pandemic Testing Board and Ensuring a Sustainable Public Health Workforce
for COVID-19 and Other Biological Threats which establishes the COVID-19 Pandemic
Testing Board to oversee implementation of a clear, unified approach to testing. The
federal government will expand the rapid testing supply and double test supplies
and increase testing capacity. The Administration will also increase onshore test
manufacturing, fill testing supply shortfalls, enhance laboratory capacity to conduct
testing over the short- and long-term, and expand surveillance for hotspots and
variants.
Effectively distribute tests and expand access to testing. The federal government
will support school screening testing programs to help schools reopen. The
Administration will also stand up a dedicated CDC Testing Support Team, fund rapid
test acquisition and distribution for priority populations, work to spur development
and manufacturing of at-home tests and work to ensure that tests are widely
available. Through Executive Order Establishing the National Pandemic Testing Board
and Ensuring a Sustainable Public Health Workforce for COVID-19 and Other Biological
Threats the President will direct agencies to facilitate testing free of charge for those
who lack health insurance and to clarify insurers’ obligation to cover testing. The
11 |
federal government will also provide testing protocols to inform the use of testing
in congregate settings, schools, and other critical areas and among asymptomatic
individuals. Further, technical assistance will support more widespread adoption of
testing to improve timely diagnosis and public confidence in the safety of settings like
schools.
Another executive order will create a Pandemic Testing Board, which will aim to increase testing capacity, expand the public health workforce, support COVID-19 screening in schools and collect data on re-openings.
https://seekingalpha.com/news/3652988-covid-response-biden-to-use-defense-production-act-executive-actions?mail_subject=apt-covid-response-biden-to-use-defense-production-act-executive-actions&utm_campaign=rta-stock-news&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha
Opti
They voted against Trump. "anyone but Trump" was the mantra.
Hoping Biden will be a moderate. Watch for the left to disown him within 90 days.
Who are they going to blame now that Trump is gone?
Opti
President-elect Joe Biden will unveil a massive multitrillion dollar stimulus package proposal on Thursday evening that aims to combat the coronavirus and begins to pump up an economy severely battered by the worst pandemic to strike the globe in a century.
The president, in an address to the nation from his hometown of Wilmington, Del., is expected to spell out his plans to speed up the nation’s COVID vaccination program, boost coronavirus testing capacity to help reopen businesses and schools, provide for $1,400 stimulus checks for Americans and federal funds for state and local governments to use to avoid laying off police officers, fire fighters and other first responders, as well as teachers and health workers.
https://www.foxbusiness.com/politics/biden-unveils-rescue-plan-america
Opti
Hoping to see contracts. So many opportunities
The US will require a negative COVID-19 test from international travelers starting January 26
bchang@businessinsider.com (Brittany Chang) 3 hrs ago
COVID-19 test from international travelers starting January 26
© ANDREW CABALLERO-REYNOLDS/AFP via Getty Images Passengers in a Dulles International airport terminal on December 27, 2020. ANDREW CABALLERO-REYNOLDS/AFP via Getty Images
• The US Centers for Disease Control and Prevention will begin requiring negative COVID-19 tests from all travelers entering the US starting January 26.
• International travelers must provide proof of COVID-19 recovery or present a negative COVID-19 test in order to board the plane.
• "Testing before and after travel is a critical layer to slow the introduction and spread of COVID-19," the CDC said in an email statement sent to Insider. "This strategy is consistent with the current phase of the pandemic and more efficiently protects the health of Americans."
• Visit Business Insider's homepage for more stories.
The US Centers for Disease Control and Prevention will begin requiring a negative COVID-19 test from international travelers.
Robert R. Redfield, the CDC director, is set to sign the order on January 12. It will then be implemented starting January 26.
This order - which was first reported by Wall Street Journal - builds upon the CDC's recent decision to require all passengers flying into the US from the UK to show a negative COVID-19 test prior to boarding, a call that was made following detections of a new, more transmissible coronavirus strain in the UK.
"Testing before and after travel is a critical layer to slow the introduction and spread of COVID-19," the CDC said in an email statement sent to Insider. "This strategy is consistent with the current phase of the pandemic and more efficiently protects the health of Americans."
According to the statement from the CDC, the decision to require negative COVID-19 tests from all passengers flying into the US was made in hopes of decreasing the spread of the virus while the government continues its mass vaccination efforts.
Travelers looking to fly to the US will have to obtain a negative viral test within three days prior to the flight. The travelers will then have to provide a copy of the lab test results to the airlines or provide documented proof of having recovered from the virus.
Airlines are then responsible for confirming the traveler's test results or proof of recovery before the passenger boards. Potential passengers that don't provide proof of COVID-19 recovery or present a negative test will not be allowed to board the aircraft.
The CDC further advises both getting another COVID-19 test three to five days after arriving, and staying home for a week.
"Testing does not eliminate all risk but when combined with a period of staying at home and everyday precautions like wearing masks and social distancing, it can make travel safer, healthier, and more responsible by reducing spread on planes, in airports, and at destinations," Robert R. Redfield, the CDC director, said in a statement.
The US isn't the only country mandating negative coronavirus tests from international travelers. Countries like Japan, Australia, Turkey, Taiwan, and even the UK currently have the same testing mandate.
Co-Diagnostics: Additional Factors For Consideration In The Investment Debate
Jan. 12, 2021 11:41 AM ETCo-Diagnostics, Inc. (CODX)3 Likes
Summary
Co-Diagnostics is well positioned to benefit from incremental fundamental momentum seen at the back end of 2020.
The company's Covid-19 tests are differentiated by distinguishing between common cold and SARS-CoV-2 with an easy to use platform.
Given the epidemiology of the common cold and influenza A+B, testing volumes will likely remain high as an exclusion barrier to Covid-19 spread.
We feel the market is unfairly discounting shares and believe shares are worth ~13-$20 in the base and upside case.
Here, we provide investors with additional factors for consideration in the investment debate.
https://seekingalpha.com/article/4398521-co-diagnostics-additional-factors-for-consideration-in-investment-debate?mail_subject=codx-co-diagnostics-additional-factors-for-consideration-in-the-investment-debate&utm_campaign=rta-stock-article&utm_content=link-2&utm_medium=email&utm_source=seeking_alpha
Opti
Co-Diagnostics to report highest quarterly revenue in Q4 2020
Jan. 06, 2021 10:18 AM ETCo-Diagnostics, Inc. (CODX)By: Dulan Lokuwithana, SA News Editor
Citing preliminary internal financial reporting, Co-Diagnostics (CODX -0.9%) says it expects Q4 2020 revenue to be the highest quarterly revenue in the company’s history.
Estimating a 20 – 25% growth over the Q3 2020 revenue of $21.8M, the revenue projected at $26.2 – 27.3M for the final quarter is on track to exceed the upper end of the analyst forecasts at $24 – 25M, the company said in a statement.
"We believe that the recent global surges of COVID-19 have played a large part in increased quarter-over-quarter revenues beating analyst estimates,” says Dwight Ega, CEO of Co-Diagnostics.
The forecasts suggest that the company could report $73.7 – 74.7M revenue for 2020, over three hundred times the revenue in 2020. The shares of Co-Diagnostics has risen ~1,040.5% over the past 12-months.
https://seekingalpha.com/news/3649284-co-diagnostics-to-report-highest-quarterly-revenue-in-q4-2020?mail_subject=codx-co-diagnostics-to-report-highest-quarterly-revenue-in-q4-2020&utm_campaign=rta-stock-news&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha
Opti
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products
SALT LAKE CITY, Jan. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial reporting for the fourth quarter 2020, unaudited quarterly revenue is anticipated to be the highest in the Company's history and to surpass analyst estimates.
Analysts' estimates for the fourth quarter ranged from $24 million to $25.98 million. Quarterly revenue is anticipated to exceed the highest estimate and to show 20-25% growth over third quarter 2020 revenue of $21.82 million.
Dwight Egan, Co-Diagnostics CEO, remarked, "We believe that the recent global surges of COVID-19 have played a large part in increased quarter-over-quarter revenues beating analyst estimates. We are grateful to see that our diagnostic products are being used for COVID-19 testing, and we remain committed to doing our part to stop this global pandemic."
The preliminary unaudited financial information for the quarter ended December 31, 2020 above is derived from the Company's preliminary internal financial reports and is subject to revision based on the completion of its quarter-end accounting and financial reporting processes necessary to finalize financial statements as of and for the quarter ended December 31, 2020. There can be no assurance that final fourth quarter results will not differ materially from these estimated results when we report the final results for the quarter.
Opti
No word yet. We need a good lawyer.
Seems to be a bit of a conundrum here. Can't sell for a loss; can't declare the stock worthless for a loss, since the company still exists.
I need the loss to offset gains from other stocks.
What to do in my eTrade acccount.
Opti
Biden plans to Increase Testing
“You will see him invoking the Defense Production Act,” Dr. Celine Gounder said on Squawk Box in response to a question about what “policy levers could be pulled that haven’t yet already been tried.”
“The idea there is to make sure the personal protective equipment, the test capacity and the raw materials for the vaccines are produced in adequate supply,” Gounder said. She also said there would be a “major increase in testing” to ferret out “invisible . . . mild and asymptomatic cases” which are helping drive the spread of the oftentimes deadly virus.
The best testing available to “ferret out invisible …. Mile and asymptomatic cases” is CODX?
Opti
FDA authorizes first over-the-counter at-home Covid test
The FDA on Tuesday authorized the first at-home coronavirus test people can buy without a prescription, a step that public health experts say adds a key new tool to the United States’ arsenal for combating the pandemic.
The 20-minute antigen test, made by Australia-based manufacturer Ellume, can be used by people 16 or older and children over the age of two when a sample is collected by an adult.
Public health experts have advocated for widely distributing these rapid over-the-counter antigen tests to millions of households, arguing near-instant results would enable people to quarantine quickly after becoming infectious. The FDA is expected to authorize additional over-the-counter Covid-19 tests in the coming weeks that could bolster supply, according to industry sources.
Opti
Congress might have finally reached a deal on a new stimulus package
• Congress proposed two separate COVID stimulus packages on Monday, one that would cost $748 billion and another that would be priced at $160 billion.
• The $748 billion package includes unemployment assistance, an extension to the eviction moratorium, funding for vaccine distribution, money for small businesses, and more.
• The $160 billion package focuses on aid for state and local governments as well as liability protection for businesses against COVID-related legal action.
Another key component of the bill is the $16 billion that it will provide to states and cities for coronavirus testing and tracing, in addition to vaccine development and distribution.
Opti
Three things needed:
1. Stimulus package which calls for nationwide testing
2. FDA approval of the ABC test
3. Share volume in excess of 10 MM per day for several weeks.
Opti
And hear absolutely nothing
Opti
Will do.
I contacted a friend in DC last night and asked him for a recommendation of a law firm. Once I get a recommendation I will contact the firm and start the discussion. I have emails of promises for the entire time that the stock has been delisted. The emails have attachments from the auditors and legal counsel. Probably at least 20 emails that promise action within a week or so.
No excuse for John not completing the audits and filing for re-registration.
I will keep the board appraised.
Opti
Co-Diagnostics JV CoSara receives clearance from regulators in India for COVID-19 2-gene multiplex test
1:01 PM ET 11/25/20 | Briefing.com
Co-Diagnostics announced today that CoSara Diagnostic, its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene COVID-19 2-gene multiplex RT-PCR test as an in vitro diagnostic, intended for the qualitative detection of the SARS-CoV-2 virus.
I am reaching out to legal friends in Wash DC for recommendations of a law firm. I will update the board when I hear more.
Opti
Note: that email on P&G was from June of 2003
Opti
This was the last information I had regarding P&G. This is an email from the financial officer of OZON who has since passed away.
Thanks for thinking of me! Unfortunately, I'm still looking for work... Or at least work that pays!
As for P&G, there has been a little noise where they might be willing to "settle" the debt and Preferred stock for a permanent royalty on the sponge sanitizer and the related patent. That deal is remote, and a long way off.
Stoddard is the only guy that could pull it off, so we all wait together...
As usual, don't put to much faith in what you read in raging bull. Too much of it is just that... "bull."
We have been talking with a guy in Dallas that wants to take the company through a bankruptcy and reorganization, but I have asked him about three times for information, plans, stock exchange and issuance plans, and benefits to the existing shareholders. So far he has provided absolutely nothing. It's like I never asked... He just ignores me completely.
Anyway,
as a Director, I can't support something like that, with no idea about what he intends to do relative to the existing shareholders.
Other than that... All is quiet. I wish I had better news, believe me.
Neal